Spyre Therapeutics (FRA:3920) Forward Dividend Yield %: 0.00% (As of Jun. 30, 2026)


FRA:3920 Spyre Therapeutics Inc FRA:3920
33 GF Score
Price €77.00
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics Forward Dividend Yield %?

Spyre Therapeutics FRA:3920 33 Forward Dividend Yield % is 0.00% as of Jun. 30, 2026. GuruFocus rates FRA:3920 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 145 Biotechnology companies, Spyre Therapeutics ranks worse than 689654.48% on this metric.

As of today (2026-06-30), the Forward Annual Dividend Yield of Spyre Therapeutics is 0.00%.

As of today (2026-06-30), the Trailing Annual Dividend Yield of Spyre Therapeutics is 0.00%.

FRA:3920's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.52
* Ranked among companies with meaningful Forward Dividend Yield % only.

Spyre Therapeutics's Dividends per Share for the three months ended in Mar. 2026 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Spyre Therapeutics  (FRA:3920) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Spyre Therapeutics Forward Dividend Yield % Related Terms

FRA:3920 vs MIRM, RYTM, PTGX: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Spyre Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Forward Dividend Yield % falls into.


FRA:3920
33GF Score
Spyre Therapeutics Inc FRA:3920
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Spyre Therapeutics (FRA:3920) has a Forward Dividend Yield % of 0.00% as of Jun. 30, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #999999 out of 145 companies in the Biotechnology industry.
Is Spyre Therapeutics' Forward Dividend Yield % too high?
Spyre Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Spyre Therapeutics ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Forward Dividend Yield % compare to MIRM and RYTM?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #999999 out of 145 companies for Forward Dividend Yield %. This places Spyre Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.52, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Spyre Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Forward Dividend Yield % is 0.00% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
33GF Score

Get the complete analysis for FRA:3920

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price